Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready
Allergan Sales, LLC currently manages 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 5 pending office actions are distributed among 5 distinct examiners. The portfolio is active in 2 distinct art units. FUBARA, BLESSING M is the busiest examiner, with 1 pending action.
The count of 5 distinct examiners is equal to the number of 5 pending office actions, meaning each action is handled by a different person. This distribution suggests that the company must navigate 5 different sets of examiner preferences. The 2 distinct art units indicate that the 5 pending office actions are concentrated in a limited number of technical groups.
FUBARA, BLESSING M handles 1 pending action, which is the same as the busiest examiner pending count. This 1 pending action is a subset of the 5 pending office actions in the Biotechnology & Pharmaceuticals area. Practitioners should note that while the examiners are diverse, the 2 distinct art units may apply similar examination standards across the portfolio.
The 5 distinct examiners and 2 distinct art units define the current prosecution landscape. Because the number of examiners is higher than the number of art units, multiple examiners are operating within the same technical groups. This structure requires the applicant to monitor for potential inconsistencies in how the 2 distinct art units handle the 5 pending office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 4 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FUBARA, BLESSING M | 1 | 62.2% | +34.3% |
| PRONZATI, GINA | 1 | 66.7% | +45.9% |
| GRAY, PHILLIP A | 1 | 74.4% | +10.5% |
| CAIN, JENNIFER LYNN | 1 | 45.0% | +70.0% |
| CORDAS, EMILY ANN | 1 | 50.8% | +57.3% |
| CONNORS, ALEXANDRA F | 1 | 23.9% | +45.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18798138 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | PRONZATI, GINA | — |
| 18741546 | MULTIPLE NEEDLE INJECTOR | GRAY, PHILLIP A | — |
| 17607842 | CONDITIONED MEDIUM AND METHODS OF USE THEREOF | CORDAS, EMILY ANN | — |
| 17393356 | COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | CONNORS, ALEXANDRA F | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18947213 | TOPICAL COMPOSITION AND METHOD OF USE | FUBARA, BLESSING M | — |
| 18798138 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | PRONZATI, GINA | — |
| 18741546 | MULTIPLE NEEDLE INJECTOR | GRAY, PHILLIP A | — |
| 18458248 | Topical Hyperpigmentation Compositions and Method of Use | CAIN, JENNIFER LYNN | — |
| 17607842 | CONDITIONED MEDIUM AND METHODS OF USE THEREOF | CORDAS, EMILY ANN | — |
| 17393356 | COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | CONNORS, ALEXANDRA F | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1632 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18947213 | TOPICAL COMPOSITION AND METHOD OF USE | FUBARA, BLESSING M | — | §102§103§112DP | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18798138 | CONDITIONED MEDIUM FROM CELLS CULTURED UNDER HYPOXIC CONDITIONS AND USES THEREOF | PRONZATI, GINA | — | §102§103§112 | Non-Final OA | — | Pending | Aug 08, 2024 |
| 18741546 | MULTIPLE NEEDLE INJECTOR | GRAY, PHILLIP A | — | §102§103 | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18458248 | Topical Hyperpigmentation Compositions and Method of Use | CAIN, JENNIFER LYNN | 1655 | §103 | Non-Final OA | — | Pending | Aug 30, 2023 |
| 17607842 | CONDITIONED MEDIUM AND METHODS OF USE THEREOF | CORDAS, EMILY ANN | 1632 | §102§103§112Other | Final Rejection | — | Pending | Oct 29, 2021 |
| 17393356 | COMPOSITIONS AND METHODS FOR REDUCING INFLAMMATION | CONNORS, ALEXANDRA F | 1634 | §103§112 | Final Rejection | — | Pending | Aug 03, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial